一项关于充血性心力衰竭风险因素和结果的病例对照研究
Mohammad Shakil Ahmad1, Abdulrahman Obaid Matar Alharbi2, Abdullah Tawakul3
1Department of Family and Community Medicine, College of Medicine, Majmaah University, 11952 Majmaah, Saudi Arabia.
Reviews in cardiovascular medicine
|March 31, 2025
概括
充血性心力衰竭 (CHF) 与患有高血压和糖尿病等可修改的风险因素有关. 慢性心血管疾病患者的临床结果明显恶化,包括死亡率上升和生活质量下降,强调需要进行风险管理.
科学领域:
- 心脏病学和公共卫生
背景情况:
- 充血性心力衰竭 (CHF) 是一个与高发病率和死亡率相关的重大健康问题.
- 确定风险因素和了解CHF患者的临床结果对于有效管理至关重要.
研究的目的:
- 确定与充血性心力衰竭 (CHF) 相关的关键风险因素.
- 评估和比较诊断为CHF的患者和对照组之间的临床结果.
主要方法:
- 数据收集包括采访,体检和医疗记录的审查.
- 评估的风险变量包括高血压,糖尿病,脂质失调,烟草/酒精使用,生活方式,饮食,年龄,性别和家族病史.
- 测量结果包括死亡率 (全因和心血管),住院率,主要心血管不良事件 (MACE),生活质量 (MLHFQ) 和功能状态 (NYHA).
主要成果:
- 高血压,糖尿病,脂质失调,吸烟和身体不活动在CHF患者中明显更为普遍.
- 慢性心血管疾病的病例显示出更高的住院率,更长的住院时间,增加了30天的再住院,以及更多的ICU入院.
- 所有原因死亡率,心血管死亡率,MACE,生活质量差,功能状况下降在CHF患者中显著增加.
结论:
- 与对照组相比,充血性心力衰竭患者表现出更高的可修改风险因素的流行率.
- 较差的临床结果,包括死亡率增加和生活质量降低,突出显示了对CHF综合风险管理策略的关键需求.
关键词:
充血性心力衰竭是一种糖尿病 糖尿病患者 糖尿病患者脱脂血症 (dyslipidaemia) 是一种疾病,住院治疗 住院治疗这种高血压,高血压.死亡率 死亡率人们的生活质量.有关风险因素的风险因素.吸烟是为了吸烟.更多相关视频
相关概念视频
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:26Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.2K
01:22Heart Failure Drugs: Diuretics
298
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
01:23Assessment of the Cardiovascular System I: Subjective Data
245
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
245
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
01:22Heart Failure Drugs: β-Blockers
284
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284